RYZODEG 70/30
PeakBLASUBCUTANEOUSSOLUTION
Approved
Sep 2015
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 39m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RYZODEG 70/30 is a basal-bolus insulin combination containing 70% insulin degludec (long-acting) and 30% insulin aspart (rapid-acting) administered via subcutaneous injection. It is indicated for glycemic control in patients with type 1 and type 2 diabetes mellitus. This fixed combination reduces injection burden by combining basal and mealtime insulin coverage in a single daily injection.
Peak
Product is in peak commercial stage with moderate competitive pressure (30/100), indicating mature market presence and stable team structure.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on RYZODEG 70/30 offers exposure to peak-stage product management in the competitive diabetes insulin category. Career growth will depend on defending market share against newer GLP-1 therapies and managing competitive dynamics in a mature segment.
Brand ManagerMedical Science Liaison
Worked on RYZODEG 70/30 at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.